Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 61

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 61
---
      
  in assessing growth hormone deficiency in children” with docket number 17/375,709 was filed on July 14, 2021, drawing the priority  
  of the provisional application and granted as US patent 11,644,474 on May 9, 2023.                                                  
  An international PCT application with docket number PCT/EP2020/070691                                                               
  was filed on July 22, 2020. Based on the PCT application several national applications have been filed in due time.                 
  On February 5, 2024, following examination of Korean patent application                                                             
  10-2021-7043189, the Korean patent 10-2635025 has been granted.                                                                     
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  A related U. S. provisional application Serial No. 63/054,889 was filed                                                             

Pressurized Gas eXpanded Technology

During the year ended December 31, 2014, and as
amended on February 2, 2015, Ceapro entered into a licence agreement with the University of Alberta (the “ PGX
Agreement”) for the rights to an enabling technology, PGX, allowing the development, production, and commercialization of
powder formulations that could be used as active ingredients for all industrial applications. PGX is a patented platform technology
that simultaneously purifies, micronizes, dries, and combines aqueous solutions of biopolymers into fine structured open porous
materials with unique morphologies using carbon dioxide (CO2) and food grade ethanol at mild temperatures. The technology can
overcome some of the challenges associated with the drying of high molecular weight biopolymers using conventional technologies. The
moderate PGX processing conditions minimizes any potential degradation. The PGX drying process can also reduce the required carbon
footprint, increase product shelf-life and lead to novel high value products including functional foods, nutraceuticals,
cosmeceuticals and pharmaceuticals. The resulting matrix also has increased surface area that can be loaded with actives using an
impregnation technology that was perfected by Ceapro and this becomes a unique enabling technology that can be used to produce
innovative delivery systems. The PGX Agreement expires after a term of 20 years or after the expiration of the last patent obtained,
whichever event shall occur first.

  42